SGS's Quay Pharma has partnered with Intract Pharma, CPI and Pharmidex to successfully repackage the biologic drug infliximab into a safer, more effective and more convenient oral capsule.
SGS's Quay Pharma, a leading pharmaceutical contract development and manufacturing organization (CDMO), has received the Queen's Award for Enterprise.
Contract development and manufacturing organization (CDMO) SGS Quay Pharma has signed a contract with Korean drug development specialist Liveome for the formulation development and clinical manufacture of a targeted release formulation for the treatment of inflammatory bowel disease containing lyophilized microbial cells suitable for phase one clinical trials. The drug substance is being supplied by Australia-based Luina Bio.
Quay Pharma has established specialist GMP suites at its facility in Deeside, Flintshire as part of an investment in their live biotherapeutics services.